Європейський Союз - англійська - EMA (European Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevulinic acid hydrochloride - glioma - antineoplastic agents - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (world health organization grade iii and iv).

Ізраїль - англійська - Ministry of Health

kivema ltd - xylometazoline hydrochloride - spray - xylometazoline hydrochloride 1 mg/ml - xylometazoline - xylometazoline - rapid relief of nasal congestion for up to ten hours.

Європейський Союз - англійська - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulinic acid hydrochloride - keratosis, actinic; carcinoma, basal cell - antineoplastic agents - treatment of actinic keratosis of mild to moderate severity on the face and scalp (olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.

Європейський Союз - англійська - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Європейський Союз - англійська - EMA (European Medicines Agency)

ratiopharm gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - immunostimulants, - filgrastim ratiopharm is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.filgrastim ratiopharm is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim ratiopharm is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.filgrastim ratiopharm is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Європейський Союз - англійська - EMA (European Medicines Agency)

eisai gmbh - perampanel - epilepsies, partial - antiepileptics, , other antiepileptics - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Європейський Союз - англійська - EMA (European Medicines Agency)

eisai gmbh - rufinamide - epilepsy - antiepileptics, - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 4 years of age and older.

Європейський Союз - англійська - EMA (European Medicines Agency)

passauer pharma gmbh - mycophenolate mofetil - graft rejection - immunosuppressants - myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.,

Європейський Союз - англійська - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analgesics - ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (it) analgesia.

Європейський Союз - англійська - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastic agents - panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (aids)-related kaposi's sarcoma (ks) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral ks is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.